Neuronautix · 2026-06-04
FAIR metadata as the infrastructure for better animal research, guideline-aware reporting, and virtual control groups.
Damien Huzard, PhD · Neuronautix
The ethical argument
Animals are used because the experiment is expected to generate knowledge that cannot be obtained otherwise. If that knowledge is lost, poorly described, or impossible to reproduce — the justification weakens. Poor data stewardship is not a technical inconvenience: it is an ethical failure.
The fragmented environment
Ethics applications
PDF protocols
Colony management systems
ELN notebooks
Spreadsheets
Email threads
Manuscript drafts
Experimental unit definition
Cage-level confounders
Humane endpoint criteria
Exclusion rule provenance
Analysis plan versioning
Raw-to-reported linkage
The reproducibility gap
Replication in preclinical cancer biology
Limited
The Reproducibility Project: Cancer Biology found replication more limited and complex than expected. Errington et al., eLife 2021.
Cost of irreproducibility
Significant
Freedman et al. (2015) estimated that irreproducibility carries a major economic cost in preclinical research investment.
Root cause
Metadata
Missing experimental context — housing, procedures, analysis pipeline — is a primary driver of non-reproducible findings.
The framework
PREPARE · ARRIVE · 3Rs
Prospective planning. Quality built in before the first animal is used. Requires structured metadata at the design stage.
Transparent reporting. The Essential 10 and Recommended Set demand structured evidence that can only come from prospective capture.
Replacement, Reduction, Refinement — all three increasingly depend on data infrastructure to be operationally meaningful.
FAIR metadata makes all three operational — computable, auditable, reusable.
Before the experiment
Literature basis, hypothesis, expected effect size
Sample size calculation, animal-level vs. cage-level distinction
Blinding and randomisation scheme; pre-specified exclusion criteria
Severity classification, welfare monitoring plan, decision triggers
Housing metadata, welfare monitoring, data archiving plan
A PREPARE-aware system flags missing information — statistical risks, welfare gaps, reuse opportunities — before data collection begins.
During the experiment
ARRIVE addressed retroactively at manuscript stage
Key information dispersed, forgotten, or reconstructed
Allocation records separated from analysis
Exclusion criteria undocumented or post-hoc
Randomization method captured at execution
Blinding scope recorded per stage
Exclusion criteria pre-specified and linked
Sample-size rationale versioned before analysis
Standards
Layer 1 — Minimum
MNMS
Minimal enforced fields for nonclinical in vivo data (Moresis et al., 2024)
Layer 2 — Domain
NWB · SEND · HCM schema
Modality-specific deep metadata for neurophysiology, toxicology, home-cage monitoring
Layer 3 — Semantic
Ontologies · CVs
Controlled vocabularies and ontologies for cross-study interoperability
Layer 4 — Exchange
JSON-LD · RO-Crate · ISA-Tab
Machine-actionable formats; experimental context travels with the data
Timing is everything
Retrospective
After the experiment
Fix metadata at publication stage — expensive, incomplete, often impossible.
Born-FAIR
From study design
Metadata captured at planning stage and maintained throughout the research lifecycle.
AI-ready
Beyond compliance
Only prospective metadata creates datasets suitable for model training and cross-study reuse.
The longer-term case
Well-curated historical control data can reduce or replace concurrent control animals. But this requires: strict metadata harmonization, pre-specified eligibility criteria, comparability diagnostics, uncertainty-aware statistics, leave-one-study-out validation, and clear limits of applicability.
FAIR metadata is necessary but not sufficient. Virtual control groups also require statistical qualification and regulatory or institutional validation before any animal reduction claim can be made.
Regulatory momentum
Steger-Hartmann et al. (ALTEX) — virtual control groups for nonclinical toxicology.
Building technical and regulatory infrastructure for VCGs to reduce animal use across nonclinical safety studies.
VCGs supported as replacement for concurrent controls in rat non-GLP dose-range-finding studies. First regulatory milestone.
Context of use: standardized nonclinical tox. Behavioral neuroscience requires additional metadata standards and validation.
Implementation
Damien Huzard, PhD · Neuronautix · 2026-06-04
neuronautix.com/contact